← All diseases
Rare and hereditary disorders
Hereditary ATTR amyloidosis
Do you want to receive a message when there is new research on Hereditary ATTR Amyloidosis? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, a summary sentence appears above each publication explaining what was studied — and you'll be notified as soon as new research on Hereditary ATTR Amyloidosis is published. View what Premium costs.
Publications (1019)
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Comparative Outcomes and Cardiac Imaging Features in Light Chain Versus Transthyretin Cardiac Amyloidosis: A Multicenter Retrospective Cohort Study. (2025/12/15) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Long-term follow-up with magnetic resonance neurography in a patient with hereditary transthyretin amyloidosis treated with inotersen. (2025/12/15) ♡
- Clinical and genetic analysis of a family with transthyretin amyloid polyneuropathy caused by a TTR Lys55Asn mutation. (2025/12/12) ♡
- Efficacy and safety of patisiran for the treatment of acquired amyloid polyneuropathy in domino liver transplant recipients. (2025/12/10) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Misdiagnosis of 99mTc-PYP-positive Danon disease as ATTR-CA: a case report and molecular imaging pitfalls. (2025/12/09) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Concurrent light chain and transthyretin cardiac amyloidosis: A case report and review of the literature. (2025/12/05) ♡
- Structural and molecular homogeneity of ATTRv-T60A amyloid fibrils across patients and organs. (2025/12/04) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [Targeted therapies in transthyretin cardiac amyloidosis: a review of the contemporary clinical context]. (2025/12/03) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort Study. (2025/12/02) ♡
- Simplified dual-time-point (99m)Tc-pyrophosphate scintigraphy in patients with suspected transthyretin amyloid cardiomyopathy: A single center series. (2025/12/01) ♡
- Outpatient worsening of heart failure and mortality in transthyretin amyloid cardiomyopathy. (2025/12/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Transthyretin serum levels and clinical outcomes in patients with transthyretin amyloid cardiomyopathy. (2025/12/01) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Transthyretin stabilizer targeting for transthyretin amyloid cardiomyopathy: A systematic review and meta-analysis. (2025/12/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CM. (2025/12/01) ♡
- Artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis. (2025/12/01) ♡
- Dual amyloidosis: A clinicopathologic and proteomic analysis of 111 patients. (2025/12/01) ♡
- Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial. (2025/12/01) ♡
- Left ventricular transthyretin amyloid load and apical sparing in patients with newly confirmed transthyretin amyloid cardiomyopathy. (2025/12/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Navigating the emerging landscape of asymptomatic ATTR-CM: challenges, opportunities and the path ahead. (2025/12/01) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Real-world effectiveness of targeted therapies in ATTR cardiomyopathy: A meta-analysis integrating population-based data. (2025/12/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis. (2025/12/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Impact of High-Dose Tafamidis on Hereditary ATTR (ATTRv) Amyloidosis With Central Nervous System Involvement: Two Case Reports With Clinical, Radiological and Cerebrospinal Fluid Follow Up. (2025/12/01) ♡
- [Acoramidis (Beyonttra®) : a new era in the treatment of transthyretin amyloid cardiomyopathy]. (2025/12/01) ♡
- [Tafamidis between real-world evidence and registration trials: towards a price renegotiation with a view to sustainability and appropriateness]. (2025/12/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Atypical gastrointestinal presentation of hereditary transthyretin amyloidosis: a case report highlighting the diagnostic challenge. (2025/11/29) ♡
- Nodular amyloid deposits with collagen fibre rupture in tenosynovial carpal tissues are associated with transthyretin cardiomyopathy: a single-centre prospective diagnostic study. (2025/11/28) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. The left ventricular mechanical dispersion as a marker of disease severity in transthyretin cardiac amyloidosis. (2025/11/27) ♡
- Distinct disruption mechanisms of green tea extracts EGC and EGCG on ATTR fibrils: a molecular simulation study. (2025/11/26) ♡
- Glycosidic scaffold bearing multiple galloyl moieties from pomegranate disrupts transthyretin amyloids. (2025/11/21) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Cardiac Resynchronization Therapy, Remodeling, and Outcome in Patients With Amyloid Transthyretin Cardiomyopathy. (2025/11/18) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [Transthyretin amyloid cardiomyopathy]. (2025/11/17) ♡
- Early nociceptive evoked potentials in symptomatic and asymptomatic transthyretin mutation carriers. (2025/11/17) ♡
- Cardiovascular determinants of the 6-minute walk distance in cardiac transthyretin amyloidosis. (2025/11/14) ♡
- Living with Transthyretin amyloid cardiomyopathy from a patient perspective. (2025/11/12) ♡
- Profibrotic Biomarkers Correlate with Clinical Presentation and Outcome in Cardiac Transthyretin Amyloidosis. (2025/11/04) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Acquired and Genetic Amyloid Neuropathies. (2025/11/01) ♡
- Polyneuropathy in Wild-Type Transthyretin Amyloidosis. (2025/11/01) ♡
- Prevalence of subclinical pulmonary transthyretin amyloidosis in a pathology-based elderly cohort: the diagnostic value of routine amyloid staining. (2025/11/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Diagnostic & therapeutic challenges of presymptomatic hereditary transthyretin amyloidosis. (2025/11/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Neurohormonal therapies at baseline and follow-up and survival in wild-type transthyretin cardiac amyloidosis. (2025/11/01) ♡
- Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Methods of identifying transthyretin amyloid cardiomyopathy in secondary data sources: a systematic review. (2025/11/01) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Drugs for transthyretin amyloidosis under the microscope: Survival, safety, and a meta-analysis with certainty of evidence assessment. (2025/11/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Evaluation of autonomic dysfunction in hereditary transthyretin amyloidosis. (2025/11/01) ♡
- Applicability of phase 3 trial selection criteria to real-world transthyretin amyloid cardiomyopathy patients. (2025/10/29) ♡
- Rac1 inhibition prevents axonal cytoskeleton dysfunction in transthyretin amyloid polyneuropathy. (2025/10/28) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The Weight of Comorbidities in the Specific Treatment of ATTR-Related Amyloid Cardiomyopathy. (2025/10/25) ♡
- Progression of QRS duration - a potential surrogate marker of survival in ATTRwt amyloidosis patients. (2025/10/20) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Idiopathic polyneuropathy with neurogenic autonomic failure - an early manifestation of Lewy body disease? a case report. (2025/10/17) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Multisystemic manifestations of a rare Glu89Lys (p. Glu109Lys) transthyretin amyloidosis: a case report of an East Asian female. (2025/10/17) ♡
- Peripheral Nerve Ultrasound Findings in Hereditary Transthyretin Amyloidosis in Brazil. (2025/10/10) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.